Myriad Genetics (MYGN) Payables (2016 - 2025)
Historic Payables for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $31.8 million.
- Myriad Genetics' Payables rose 743.24% to $31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.8 million, marking a year-over-year increase of 743.24%. This contributed to the annual value of $32.3 million for FY2024, which is 2519.38% up from last year.
- Myriad Genetics' Payables amounted to $31.8 million in Q3 2025, which was up 743.24% from $30.9 million recorded in Q2 2025.
- In the past 5 years, Myriad Genetics' Payables registered a high of $39.8 million during Q2 2023, and its lowest value of $15.7 million during Q3 2021.
- Over the past 5 years, Myriad Genetics' median Payables value was $29.6 million (recorded in 2021), while the average stood at $29.3 million.
- As far as peak fluctuations go, Myriad Genetics' Payables crashed by 3135.31% in 2021, and later skyrocketed by 8853.5% in 2022.
- Quarter analysis of 5 years shows Myriad Genetics' Payables stood at $29.6 million in 2021, then dropped by 2.7% to $28.8 million in 2022, then dropped by 10.42% to $25.8 million in 2023, then grew by 25.19% to $32.3 million in 2024, then dropped by 1.55% to $31.8 million in 2025.
- Its Payables was $31.8 million in Q3 2025, compared to $30.9 million in Q2 2025 and $28.1 million in Q1 2025.